US2015105467A1PendingUtilityA1

Formulations of low dose diclofenac and beta-cyclodextrin

61
Assignee: JAVELIN PHARMACEUTICALS INCPriority: Mar 28, 2006Filed: Dec 19, 2014Published: Apr 16, 2015
Est. expiryMar 28, 2026(expired)· nominal 20-yr term from priority
Inventors:Curtis WrightDaniel B. CarrFred H. Mermelstein
A61P 25/04A61P 29/00C07H 15/04A61K 31/195A61K 31/196A61K 9/02A61K 9/14A61K 2300/00A61K 47/40A61K 31/724C07H 3/06A61K 9/0019C08B 37/0015A61K 9/08
61
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention is directed to a pharmaceutical composition containing a unit dose of a diclofenac compound effective to induce analgesia; and a beta-cyclodextrin compound; wherein the dose of the diclofenac compound is less than 10 mg. The present invention is also directed to methods of treating a subject in need of analgesia with the pharmaceutical compositions of the invention.

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
         1 . A pharmaceutical composition comprising from about 18.75 mg to about 37.5 mg of a diclofenac compound solubilized with a beta-cyclodextrin compound. 
     
     
         2 . The pharmaceutical composition of  claim 1 , wherein the diclofenac compound is diclofenac sodium. 
     
     
         3 . The pharmaceutical composition of  claim 1 , wherein the beta-cyclodextrin compound is hydroxypropyl beta-cyclodextrin. 
     
     
         4 . The pharmaceutical composition of  claim 1 , wherein the pharmaceutical composition is formulated for a parenteral route of administration. 
     
     
         5 . The pharmaceutical composition of  claim 1 , wherein the dose of the diclofenac compound is about 18.75 mg. 
     
     
         6 . The pharmaceutical composition of  claim 1 , wherein the dose diclofenac compound is about 37.5 mg. 
     
     
         7 . The pharmaceutical composition of  claim 1 , further comprising a stabilizer. 
     
     
         8 . The pharmaceutical composition of  claim 4 , wherein the parenteral route of administration is intravenous or intramuscular. 
     
     
         9 . The pharmaceutical composition of  claim 1 , wherein the composition is stable at room temperature.

Join the waitlist — get patent alerts

Track US2015105467A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.